Background
==========

Ecological studies reporting a correlation between lower solar ultraviolet-B exposure and higher breast cancer incidence and/or mortality \[[@B1]-[@B3]\] contributed to the hypothesis that vitamin D may reduce breast cancer risk \[[@B4]\]. Results from retrospective case--control studies are also suggestive of an inverse association of vitamin D intake \[[@B5]\] and circulating 25-hydroxyvitamin D (25(OH)D) \[[@B6]-[@B8]\] with the risk of breast cancer. However, results from cohort studies \[[@B9]-[@B16]\] and intervention trials \[[@B17],[@B18]\] of the association of circulating vitamin D with breast cancer incidence have been generally null \[[@B7],[@B8]\].

Epidemiological studies of the association of vitamin D with disease are complicated because circulating vitamin D levels are determined by a variety of factors, including ultraviolet radiation exposure, skin sensitivity to sun exposure, and diet \[[@B19]-[@B22]\]. Most investigations examining vitamin D and breast cancer risk have been conducted in whites, however; and circulating levels of 25(OH)D, the most reliable indicator of vitamin D status, are known to differ substantially between race/ethnic groups with varying diets and ability to synthesize vitamin D in the skin \[[@B19],[@B21],[@B23]\].

Among several forms of vitamin D, the two major forms are vitamin D3 (cholecalciferol) and vitamin D2 (ergocalciferol). Vitamin D3 is synthesized mostly from the irradiation of 7-hydrocholesterol on the skin and only a few foods naturally contain vitamin D3. In contrast, vitamin D2, at lower circulating levels than vitamin D3, is obtained from intake of foods, fortified products, and supplements. Since skin color is a determinant of synthesis to vitamin D3, it is important to examine the potential modifying influence of race/ethnicity on the relation of circulating vitamin D to disease risk. Specifically, it is unknown whether 25-hydroxyvitamin D2 (25(OH)D~2~) interacts with race/ethnicity on the association of vitamin D with breast cancer risk.

It is plausible that the association of plasma 25-hydroxyvitamin D3 25(OH)D~3~ and 25(OH)D with breast cancer risk is non-linear, and a minimum threshold is needed for vitamin D to exert a protective effect \[[@B5]\]. In this regard, the lower cutoff values that classify vitamin D levels as inadequate or deficient, recently suggested by the Institute of Medicine \[[@B24],[@B25]\] and the Endocrine Society \[[@B26]\], were determined based on previous studies of skeletal health, the results of which may not be directly relevant to breast cancer risk.

We conducted a nested case--control study within the Multiethnic Cohort (MEC) in Hawaii and Los Angeles to test the hypothesis that pre-diagnostic plasma levels of 25(OH)D~2~ and 25(OH)D~3~ are associated with the risk of postmenopausal breast cancer, and that this association varies by race/ethnic group in populations with relatively high year-round levels of sunlight.

Methods
=======

The MEC is a prospective study of more than 215,000 adults from five race/ethnic groups (white, African-American, Native Hawaiian, Japanese, Latino) in Hawaii and Los Angeles that was established between 1993 and 1996 to examine the association of lifestyle and genes with chronic disease risk \[[@B27]\]. A biospecimen repository was developed within the MEC between 2001 and 2006 including 36,458 postmenopausal women, ages 45--75 years, who agreed to provide blood specimens and a short interview. The MEC was approved by the Institutional Review Boards of the University of Hawaii and the University of Southern California.

Incident invasive breast cancer cases were identified by linkage to the Surveillance, Epidemiology, and End Results Program registries in the states of Hawaii and California through October, 2010, including 729 eligible postmenopausal women with a diagnosis of invasive breast cancer. Controls who were alive and free of breast cancer were randomly selected from the pool of postmenopausal women in the biospecimen repository and matched 1:1 to each case within strata of geographic location (Hawaii or California), race/ethnicity, birth year (±1 y), date of blood draw (±6 mo), time of blood draw (±2 h), hours fasting prior to blood draw (0- \< 6, 6- \< 8, 8- \< 10, and ≥10 h), and hormone replacement therapy use (HRT; as current versus not current). Matched pairs that included a case or control with 25(OH)D~2~ or 25(OH)D~3~ measurements below the limits of detection (10 cases and 10 controls), or outliers (higher levels than three standard deviation (3 cases for 25(OH)D~2~, none for 25(OH)D~3~)), were excluded. After exclusion, 707 matched sets remained for statistical analysis.

Plasma levels of 25(OH)D~2~ and 25(OH)D~3~ were analyzed by isotope dilution liquid chromatography orbitrap mass spectrometry (Laboratory of AAF, ThermoFisher Scientific, Waltham, MA). The assay was validated by the Vitamin D External Quality Assessment Scheme (DEQAS) and National Institute of Standards and Technology (NIST) quality assurance programs. Intra- and inter-assay variability coefficients of variations of 25(OH)D which was the sum of 25(OH)D~2~ and 25(OH)D~3~, were 6.8% and 7.4%, based on the analysis of 47 duplicate and 23 triplicate samples.

Conditional logistic regression with matched sets as strata was used to compute odds ratios (ORs) and 95% confidence intervals (CIs). Levels of 25(OH)D~2~ were coded as a binary variable (0, \>0 ng/mL) because the detection level of 25(OH)D~2~ was low. For 25(OH)D~3~ and 25(OH)D, we used continuous variables (10 ng/mL and 20 ng/mL) to facilitate comparison with our results and results from the latest meta-analyses \[[@B7],[@B8]\]. For 25(OH)D, binary variables using several cutoffs (16, 20, and 30 ng/mL) were also used based on the recent definition of vitamin D deficiency or insufficiency \[[@B25],[@B26]\]. Heterogeneity of effect across race/ethnic groups was tested by the Wald test of the cross-product terms for vitamin D and ethnic group. All statistical models were adjusted for potential confounders, including body mass index (\<25.0, 25.0-29.9, ≥30.0 kg/m^2^), number of live births (never, 1, 2--3, ≥4, missing), family history of breast cancer (yes, no, missing), use of multivitamin and calcium supplements (yes: taken at least once a week in the last year preceding blood draw; no; missing), season (October to March, April to September), sunburn history (yes, no, missing), and engagement in strenuous sports (never, ≤1 h/week, \>1 h/week, missing). The study participants were queried about the frequency and duration of intake of calcium supplements regardless of alone or in combination with vitamin D.

Sensitivity analyses for 25(OH)D~3~ and 25(OH)D were performed among whites by excluding women (by case--control pair) within 6 months, one, two, three, and four years from the date of blood draw. To find the change-point in ORs to identify a threshold effect of 25(OH)D~3~ and 25(OH)D on breast cancer risk, we implemented a two-segmented piecewise-linear logistic regression for each race/ethnic group \[[@B28]\].

Results
=======

The mean age of the study subjects was 67.8 years (Table [1](#T1){ref-type="table"}) and the mean time between the date of blood draw and the date of breast cancer diagnosis was 3.1 years. Compared to controls, in all five race/ethnic groups, cases were likely to be overweight and obese or to have a family history of breast cancer. Dietary and supplementary intake for energy, vitamin D and calcium was not different between cases and controls in every race/ethnic group. Among controls, the mean plasma 25(OH)D~2~ levels were the highest among African-Americans and Japanese, and the lowest among whites. In contrast, mean plasma 25(OH)D~3~ and 25(OH)D levels were the highest among whites and the lowest among African-Americans.

###### 

Basic characteristics of postmenopausal breast cancer cases and controls by race/ethnicity

                                      **White**   **African-American**   **Native Hawaiian**   **Japanese**   **Latino**                                                                                                                                             
  --------------------------------- ----------- ---------------------- --------------------- -------------- ------------ -------- ---------- -------- ---------- -------- ---------- -------- ---------- -------- ---------- -------- ---------- -------- ---------- --------
  Area                                                                                                                                                                                                                                                                       
   Hawaii                                   137                   93.2                   137           93.2                                                   68    100.0         68    100.0        215     84.6        215     84.6                                        
   LA                                        10                    6.8                    10            6.8          106    100.0        106    100.0                                                 39     15.4         39     15.4        132    100.0        132    100.0
  Season                                                                                                                                                                                                                                                                     
   Oct-Mar                                   65                   44.2                    68           46.3           54     50.9         57     53.8         38     55.9         36     52.9         98     38.6        119     46.8         70     53.0         57     43.2
   Apr-Sep                                   82                   55.8                    79           53.7           52     49.1         49     46.2         30     44.1         32     47.1        156     61.4        135     53.2         62     47.0         75     56.8
  Sunburn history                           103                   70.1                    98           67.1           17     16.2          9      9.0         21     31.3         23     33.8         48     19.0         54     21.4         40     32.3         28     22.8
  Family history of breast cancer            22                   15.0                    13            8.8           21     19.8         22     20.8         12     17.6         10     14.7         38     15.0         28     11.0         15     11.4          8      6.1
  Use of multivitamins                       82                   56.6                    73           50.3           59     56.7         56     55.4         36     52.9         33     49.3        135     53.4        126     50.0         63     48.8         69     52.7
  Use of calcium supplements                 68                   47.9                    62           43.4           29     29.9         38     36.9         18     26.5         28     43.1        114     45.8        139     55.6         52     42.3         48     38.4
                                       **Mean**                 **SD**              **Mean**         **SD**     **Mean**   **SD**   **Mean**   **SD**   **Mean**   **SD**   **Mean**   **SD**   **Mean**   **SD**   **Mean**   **SD**   **Mean**   **SD**   **Mean**   **SD**
  Age                                      68.5                    7.9                  68.4            7.7         69.1      7.6       69.2      7.5       65.7      6.8       65.8      6.8       67.8      7.7       67.8      7.7       67.3      6.7       67.3      6.8
  Body mass index (kg/m^2^)                25.0                    4.5                  24.5            5.4         28.0      5.0       28.4      5.7       27.8      5.5       28.1      6.2       24.2      4.2       23.3      3.8       28.2      5.7       27.3      5.6
  Live births                               2.3                    1.6                   2.7            1.6          2.9      1.8        2.9      2.0        3.5      2.0        3.5      1.7        2.2      1.4        2.3      1.4        3.5      2.0        4.1      2.0
  Sports activity (hour/week)               0.2                    0.3                   0.2            0.5          0.1      0.3        0.1      0.2        0.2      0.7        0.2      0.4        0.1      0.3        0.1      0.2        0.1      0.4        0.1      0.4
  Energy intake, Kcal/day                 1,799                    649                 1,785            714        1,848    1,043      1,834    1,010      2,295    1,191      2,031    1,092      1,814      670      1,900      658      2,189    1,199      2,222    1,369
  Vitamin D, IU/1000 Kcal/day                78                     44                    81             52           74       52         70       52         74       47         81       56         62       38         61       36         72       44         70       58
  Calcium, mg/1000 Kcal/day                 438                    136                   436            144          400      146        384      145        361      140        371      170        336      108        331      109        467      142        463      164
  Phosphorus, mg/1000 Kcal/day              650                    123                   658            122          651      137        631      129        578      124        604      139        580      101        568      104        687      127        699      144
  Plasma 25(OH)D~2~, ng/mL^a^               3.5                    5.4                   2.6            4.7          2.2      5.0        3.3      5.5        1.7      3.8        2.8      5.3        4.3      5.7        3.3      4.9        2.5      4.5        3.0      5.4
  Plasma 25(OH)D~3~, ng/mL^a^              31.4                   10.1                  34.8           10.1         23.5     12.3       23.1      9.6       30.9      9.5       30.6     11.6       28.5      9.4       29.3     10.5       25.2      8.1       24.1      8.5
  Plasma 25(OH)D, ng/mL^a^                 34.9                   10.2                  37.4            9.7         25.7     12.1       26.4     11.3       32.6      8.7       33.4     12.2       32.7      9.3       32.6     10.2       27.7      9.4       27.1      9.4

*Abbreviation*: *SD* standard deviation, *25(OH)D*~*2*~ 25-hydroxyvitamin D2, *25(OH)D*~*3*~ 25-hydroxyvitamin D3, *25(OH)D* sum of 25(OH)D~2~and 25(OH)D~3~.

^a^Multiply 2.5 to convert the values to nmol/L.

Plasma concentrations of 25(OH)D~2~ were inversely associated with breast cancer risk among African-American women (\>0 ng/mL vs 0 ng/mL: OR 0.29; 95% CI 0.12-0.70), but not among women in other race/ethnic groups (Table [2](#T2){ref-type="table"}). A unit increase of 20 ng/mL in plasma concentrations of 25(OH)D~3~ (OR 0.28; 95% CI 0.14-0.56) was inversely associated with postmenopausal breast cancer risk among white women, but not among women in other race/ethnic groups (test for heterogeneity, P = 0.007). Among whites, plasma levels of 25(OH)D considered deficient (\<20 ng/ml) led to a 7.5 times greater risk of breast cancer (95% CI 1.41-39.8) compared to women with circulating levels of 25(OH)D at 20 ng/mL or more. For women other than non-Hispanic whites, the association of plasma 25(OH)D levels with breast cancer risk was not statistically significant.

###### 

**Odds ratio (OR) and 95% confidence intervals (CI) for breast cancer by categories in circulating 25(OH)D**~**2**~**, 25(OH)D**~**3**~**, and 25(OH)D levels by race/ethnicity**^**a**^

                          **White**   **African-American**   **Native Hawaiian**   **Japanese**   **Latino**   ***Test for heterogeneity***^**b**^                                                                                                                           
  ---------------------- ----------- ---------------------- --------------------- -------------- ------------ ------------------------------------- ------ ------ --------- ------ ------ ------ --------- ------ ------ ------ --------- ------ ------ ------ ------------- -------------
  **25(OH)D**~**2**~                                                                                                                                                                                                                                                                
   0 ng/mL                  80/90             1.00                                                  85/66                     1.00                                  49/43    1.00                 124/139   1.00                  84/83    1.00                                     
   \> 0 ng/mL               67/57             1.29                  0.75               2.23         21/40                     0.29                   0.12   0.70    19/25    0.46   0.16   1.34   130/115   1.32   0.90   1.93    48/49    0.85   0.46   1.56   *P = 0.817*   *P = 0.124*
  **25(OH)D**~**3**~                                                                                                                                                                                                                                                                
   10 ng/mL increase       147/147            0.53                  0.37               0.75        106/106                    1.27                   0.91   1.76   118/118   0.89   0.59   1.34   229/229   0.92   0.75   1.12   232/232   1.29   0.87   1.89   *P = 0.059*   *P = 0.007*
   20 ng/mL increase       147/147            0.28                  0.14               0.56        106/106                    1.61                   0.83   3.11   118/118   0.80   0.35   1.79   229/229   0.84   0.57   1.24   232/232   1.65   0.76   3.57                       
  **25(OH)D**                                                                                                                                                                                                                                                                       
   10 ng/mL increase       147/147            0.66                  0.48               0.90        106/106                    1.08                   0.79   1.47   118/118   0.79   0.52   1.20   229/229   1.04   0.84   1.28   232/232   1.17   0.84   1.64   *P = 0.086*   *P = 0.051*
   20 ng/mL increase       147/147            0.43                  0.23               0.80        106/106                    1.16                   0.63   2.16   118/118   0.63   0.27   1.45   229/229   1.08   0.71   1.65   232/232   1.38   0.71   2.69                       
  Vitamin D deficiency                                                                                                                                                                                                                                                              
  Cutoff at 16 ng/mL                                                                                                                                                                                                                                                                
    ≥16 ng/mL              144/146            1.00                                                  79/85                     1.00                                  65/64    1.00                 246/245   1.00                 119/119   1.00                                     
    \<16 ng/mL               3/1              4.98                  0.40               62.1         27/21                     1.36                   0.59   3.13     3/4     1.44   0.18   11.5     8/9     0.72   0.24   2.14    13/13    1.01   0.31   3.29   *P = 0.395*   *P = 0.465*
  Cutoff at 20 ng/mL                                                                                                                                                                                                                                                                
    ≥20 ng/mL              136/145            1.00                                                  72/70                     1.00                                  64/61    1.00                 233/231   1.00                 105/102   1.00                                     
    \<20 ng/mL              11/2              7.50                  1.41               39.8         34/36                     0.74                   0.36   1.53     4/7     0.74   0.13   4.29    21/23    0.96   0.47   1.97    27/30    0.90   0.41   1.95   *P = 0.226*   *P = 0.023*
  Cutoff at 30 ng/mL                                                                                                                                                                                                                                                                
    ≥30 ng/mL              98/115             1.00                                                  29/39                     1.00                                  44/39    1.00                 152/144   1.00                  45/42    1.00                                     
    \<30 ng/mL              49/32             2.56                  1.27               5.14         77/67                     1.34                   0.64   2.79    24/29    0.64   0.28   1.49   102/110   0.86   0.58   1.29    87/90    0.76   0.40   1.46   *P = 0.025*   *P = 0.026*

*Abbreviation*: *25(OH)D*~*2*~ 25-hydroxyvitamin D2, *25(OH)D*~*3*~ 25-hydroxyvitamin D3, *25(OH)D* sum of 25(OH)D~2~ and 25(OH)D~3~.

Note. Values are given in ng/mL. Multiply 2.5 to convert the values to nmol/L.

^a^Modeled through conditional logistic regression after adjustment for season, sunburn history, body mass index, strenuous sports, number of live births, family history of breast cancer, use of multivitamin, and use of calcium supplement.

^b^Tests based on the Wald statistic for cross-product terms between ethnicity and plasma vitamin D level.

Among whites, results from a two-segmented piecewise-linear logistic regression yielded a threshold at 19.4 ng/mL for 25(OH)D~3~ (for unit increase in 25(OH)D~3~, OR 1.11, 95% CI: 0.98-1.25 below the change-point; OR 0.96, 95% CI: 0.92-0.99 above the change-point; test for heterogeneity P = 0.007) and at 19.5 ng/mL for 25(OH)D (for unit increase in 25(OH)D, OR 1.20, 95% CI: 0.97-1.48) below the change-point; OR 0.98, 95% CI: 0.95-1.01 above the change-point; test for heterogeneity P = 0.046) (data not shown). Change-points, either for 25(OH)D~3~ or for 25(OH)D, were not detected among African-American, Native Hawaiian, Japanese, or Latino women.

In sensitivity analyses, no heterogeneity by length of follow-up time after blood draw was detected in the risk estimates by a unit increase of 20 ng/mL of plasma 25(OH)D~3~ or of plasma 25(OH)D concentrations for postmenopausal breast cancer among whites (test for heterogeneity P = 0.939 for 25(OH)D~3~; P = 0.265 for 25(OH)D) (data not shown).

Discussion
==========

Results from this study add to the growing debate regarding the potential beneficial effects of vitamin D against breast cancer and other malignancies \[[@B29],[@B30]\]. Higher circulating vitamin D3 and vitamin D levels were associated with a lower risk of postmenopausal breast cancer among white women whose circulating 25(OH)D~3~ and 25(OH)D levels exceeded those of women in other race/ethnic groups.

Vitamin D3, which is the major form of vitamin D, is obtained from the diet or through synthesis in the skin from the action of ultraviolet radiation \[[@B31]\]. The inverse association found in this analysis among white women may be explained by the relatively high levels of circulating vitamin D3 achievable among whites living in Los Angeles and Hawaii where ambient levels of ultraviolet radiation are sufficiently elevated throughout the year for adequate cutaneous vitamin D production. White women in our study had higher plasma 25(OH)D levels (means of 34.9 ng/mL in cases and of 37.4 in controls) compared to white women in previous nested case--control studies, with ranges from 20.0 to 31.5 ng/mL among cases and 20.4 to 33.1 ng/mL among controls \[[@B9]-[@B15],[@B17],[@B18]\]. This observation is consistent with findings from prospective studies of dietary vitamin D, sun exposure, and breast cancer risk in France \[[@B32]\] and in the United States \[[@B33]\] which showed a lower risk of breast cancer among women who were high dietary vitamin D consumers living in southern regions, but not in northern regions, of these countries.

A meta-analysis of studies measuring plasma 25(OH)D levels and breast cancer risk reported a lower risk of breast cancer associated with a 10 ng/mL increase \[[@B7]\] or 20 ng/mL increase \[[@B8]\] in pooled estimates; however, when the pooled analysis was restricted to prospective studies, this association was null. Our data support the hypothesis that a minimum threshold level of 25(OH)D exceeding 20 ng/ml is necessary for an inverse association with postmenopausal breast cancer risk to be measurable, although the modest number of subjects below this threshold was a concern. A threshold effect rather than a dose-dependent effect of vitamin D with breast cancer risk was recently supported by a re-analysis of data from the Women\'s Health Initiative \[[@B34]\]: the beneficial effect of vitamin D on reducing breast cancer was examined among women who were not using calcium or vitamin D supplements at baseline, while higher doses of vitamin D did not further decrease breast cancer incidence among women who were using supplements at baseline.

To our knowledge, this is the first case--control study nested in a prospective cohort that examined the association between circulating vitamin D3 and vitamin D (sum of vitamin D2 vitamin D3) concentrations and breast cancer risk in a multiethnic population. Our finding that white women had the highest circulating vitamin D3 and/or vitamin D concentrations is consistent with reports from previous cross-sectional studies \[[@B21],[@B23],[@B35]-[@B38]\]. One possible explanation for the unique association of vitamin D with breast cancer risk among white women is a potential modifying effect of this association by vitamin D receptor polymorphisms (*FokI, BgII*) that vary substantially by ethnic group \[[@B39]-[@B43]\]. The vitamin D receptor binds the active form of 25(OH)D (i.e., 1,25 dihydroxyvitamin D (1,25(OH)~2~D)) in the nucleus of breast epithelial cells, thereby reducing cell proliferation, and increasing cell differentiation, autophagy and apoptosis \[[@B44]\]. However, it is also possible that light skin pigmentation combined with high sun exposure, rather than differences in vitamin D receptor polymorphisms among whites compared to other women, account for the reduction in breast cancer risk limited to this race/ethnic group \[[@B37],[@B45]\].

In contrast to the results for vitamin D3, we found that a modest reduction in the risk of breast cancer is associated with higher levels of plasma vitamin D2 among African-American women. African-Americans had the lowest plasma 25(OH)D~3~ among the five race/ethnic groups studied. It is possible that the apparent ethnic-specific effect of circulating vitamin D2 on breast cancer risk among African-American women resulted from their relatively low levels of circulating vitamin D3 compared to other race/ethnic groups which may have masked a modest association of risk with vitamin D3. Vitamin D2 (ergocalciferol) is derived from irradiation of plants or yeast and is found in humans when ingested from food or supplements \[[@B46]\]. Recent literature suggests that the binding affinity of vitamin D2 and its metabolites to plasma vitamin D binding protein is weaker than that of vitamin D3 \[[@B47],[@B48]\], but little is known about the physiologic effects or ethnic-specific potency of vitamin D2. Plasma 25(OH)D~2~ levels in our study participants were generally above the assay detection limit, although it is still possible that the association found among white women in our study resulted from chance.

Strengths of this study include its multiethnic composition, the use of pre-diagnosed biologic samples, and a relatively large number of carefully matched cases and controls. High circulating levels of vitamin D in both cases and controls may have attenuated the risk estimates, but study power remained adequate. A further strength of our analysis was the ability to adjust for body mass index, physical activity, as well as calcium and vitamin supplements, factors which are correlated with circulating 25(OH)D levels \[[@B49]\]. Because this information was gathered using a mail survey form, recall may have been imperfect. However, all women included in this analysis were healthy at the time of interview, so any biased responses would be non-differential and likely to attenuate risk estimates toward the null. The number of cases and controls in each ethnic group was not sufficient to stratify the analyses by geographical area and/or by season which is a possible limitation.

Conclusion
==========

In conclusion, plasma vitamin D was inversely associated with postmenopausal breast cancer risk among white women who reside in latitudes where levels of ultraviolet radiation are comparatively high. It is likely that a minimum threshold of vitamin D exposure from both sun and diet is required to achieve a reduction in breast cancer risk among postmenopausal white women.
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